IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) reported a meaningful turnaround in its fourth quarter 2024, capping a year of repositioning with 25% revenue growth and its first quarterly adjusted EBITDA profit in recent history.
The medical cannabis company, which is jointly headquartered in Canada and Israel, generated C$13.3 million in…
Please login to read all 451 words.






“Our results demonstrate that topical cannabinoid therapy leads to symptom remission in some cases,” investigators concluded.
Researchers acknowledged, “This lack of investment is a missed opportunity.”